Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data

• Published in: The Lancet Infectious Diseases Vol. 23; no. 7; pp. 856 - 866
• Main Authors: Wilkins, Deidre, Langedijk, Annefleur C, Lebbink, Robert Jan, Morehouse, Christopher, Abram, Michael E, Ahani, Bahar, Aksyuk, Anastasia A, Baraldi, Eugenio, Brady, Tyler, Chen, Albert Tian, Chi, Hsin, Choi, Eun Hwa, Cohen, Robert, Danilenko, Daria M, Gopalakrishnan, Vancheswaran, Greenough, Anne, Heikkinen, Terho, Hosoya, Mitsuaki, Keller, Christian, Kelly, Elizabeth J, Kragten-Tabatabaie, Leyla, Martinón-Torres, Federico, de Los Santos, Abiel Homero Mascareñas, Nunes, Marta C, Palomino, María Angélica, Papenburg, Jesse, Pernica, Jeffrey M, Richmond, Peter, Stein, Renato T, Tuffy, Kevin M, Verwey, Charl, Esser, Mark T, Tabor, David E, Bont, Louis J, Clement, Pascale, Gupta, Atul, Hashimoto, Koichi, Komissarova, Kseniya, Laubscher, Matt, Lumertz, Magali, Priante, Elena, Rivero-Calle, Irene, Wadia, Ushma, Yun, Ki Wook
• Format: Journal Article
• Language: English
• Published: United States Elsevier Ltd 01.07.2023; Elsevier BV; Elsevier Limited
• Subjects: Amino acid sequence; Amino acids; Binding Sites; Conservation; COVID-19; Disease prevention; Entropy; Epidemics; Epidemiology; Evolution; Fusion protein; Genetic diversity; Glycoproteins; Hemagglutinins; Humans; Infant; Infections; Infectious Diseases; Influenza; Monoclonal antibodies; Observational studies; Pilot Projects; Polymorphism; Prospective Studies; Proteins; Respiratory syncytial virus; Respiratory Syncytial Virus Infections; Respiratory Syncytial Virus Infections - epidemiology; Respiratory Syncytial Virus, Human; Respiratory Syncytial Virus, Human - genetics; SARS-CoV-2; Seasonal variations; Severe acute respiratory syndrome coronavirus 2; Surveillance; Viral diseases; Viruses; Netherlands
• ISSN: 1473-3099; 1474-4457; 1474-4457
• DOI: 10.1016/S1473-3099(23)00062-2

Nirsevimab is an extended half-life monoclonal antibody to the respiratory syncytial virus (RSV) fusion protein that has been developed to protect infants for an entire RSV season. Previous studies have shown that the nirsevimab binding site is highly conserved. However, investigations of the geotemporal evolution of potential escape variants in recent (ie, 2015–2021) RSV seasons have been minimal. Here, we examine prospective RSV surveillance data to assess the geotemporal prevalence of RSV A and B, and functionally characterise the effect of the nirsevimab binding-site substitutions identified between 2015 and 2021. We assessed the geotemporal prevalence of RSV A and B and nirsevimab binding-site conservation between 2015 and 2021 from three prospective RSV molecular surveillance studies (the US-based OUTSMART-RSV, the global INFORM-RSV, and a pilot study in South Africa). Nirsevimab binding-site substitutions were assessed in an RSV microneutralisation susceptibility assay. We contextualised our findings by assessing fusion-protein sequence diversity from 1956 to 2021 relative to other respiratory-virus envelope glycoproteins using RSV fusion protein sequences published in NCBI GenBank. We identified 5675 RSV A and RSV B fusion protein sequences (2875 RSV A and 2800 RSV B) from the three surveillance studies (2015–2021). Nearly all (25 [100%] of 25 positions of RSV A fusion proteins and 22 [88%] of 25 positions of RSV B fusion proteins) amino acids within the nirsevimab binding site remained highly conserved between 2015 and 2021. A highly prevalent (ie, >40·0% of all sequences) nirsevimab binding-site Ile206Met:Gln209Arg RSV B polymorphism arose between 2016 and 2021. Nirsevimab neutralised a diverse set of recombinant RSV viruses, including new variants containing binding-site substitutions. RSV B variants with reduced susceptibility to nirsevimab neutralisation were detected at low frequencies (ie, prevalence <1·0%) between 2015 and 2021. We used 3626 RSV fusion-protein sequences published in NCBI GenBank between 1956 and 2021 (2024 RSV and 1602 RSV B) to show that the RSV fusion protein had lower genetic diversity than influenza haemagglutinin and SARS-CoV-2 spike proteins. The nirsevimab binding site was highly conserved between 1956 and 2021. Nirsevimab escape variants were rare and have not increased over time. AstraZeneca and Sanofi.